---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179012"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:15:29.270538+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics shareholders approve reverse stock split authorization and up to $50M issuance to Lincoln Park

## Summary
- All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.
- Approved potential issuance of up to $50M common stock plus $1M commitment fee to Lincoln Park Capital Fund.
- Board authorized to effect a reverse stock split at a ratio between 1:2 and 1:250 within 12 months.
- Advisory vote on executive compensation passed with 16,714,842 votes for and 858,028 against.
- Fifth amendment and restatement of the 2020 Stock Incentive Plan was approved by stockholders.

## SEC filing metadata
- accession: 0001193125-25-179012
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/0001193125-25-179012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/d71976d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179012
- JSON: https://secwatch.observer/filing/0001193125-25-179012.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.